2026 NPPES data Hematology & Oncology Physician NPI 1811973084 MD
Verify on CMS →

JOHN CONTI, MD

Hematology & Oncology Physician in BELLEVILLE, New Jersey. CMS National Plan and Provider Enumeration System profile including specialty classification, practice address, and Medicare prescribing data when reported.

Federal data — no proprietary rating. PlainDoctor publishes the actual CMS NPPES and Medicare records — NPI registration, specialty, practice location, and prescribing data — without a composite score or editorial opinion on top. Every field traces to a federal source.
Prescribing volume
581
Medicare Part D claims · 122 beneficiaries · Hematology & Oncology Physician avg: 847
Generic prescribing
76%
generic claims · 24% brand-name · higher generic rates reduce patient out-of-pocket costs
MIPS score
93.0247/100
▲ 10 pts above national avg 83.1 · [object Object]
Industry payments
$865.86
46 payments · CMS Open Payments (Sunshine Act)
What the federal data reveals: JOHN CONTI, MD is a Hematology & Oncology Physician ([object Object]) practicing in BELLEVILLE, New Jersey with a Medicare Part D prescribing footprint of 581 claims across 122 beneficiaries — 24% brand-name prescribing . Their CMS MIPS Final Score of 93.0247/100 (national average: 83.1) reflects performance across Quality, Cost, Interoperability, and Improvement Activities . Industry payments of $865.86 across 46 transactions are disclosed under CMS Open Payments (Sunshine Act).

What the federal data shows

JOHN CONTI, MD reported a CMS MIPS final score of 93.0247/100 — above the 83.1 national average — and filed 581 Medicare Part D claims in 2023.

93.0247/100
MIPS score · +10 vs avg
581
Part D claims, 2023
76%
generic prescribing
Likely
board-certified (heuristic)

Every figure on this page comes straight from federal CMS records (NPPES, Medicare Part D, MIPS, Open Payments) — no proprietary rating or editorial opinion is applied.

JOHN CONTI, MD's MIPS score vs every scored U.S. clinician

CMS Merit-based Incentive Payment System (MIPS) final score, 2023 — the federal quality measure

93 Top 29% higher than 71% of 477,587 scored providers

0–10: 8,684 scored providers (2%). Below this entry. 10–20: 3,008 scored providers (1%). Below this entry. 20–30: 3,069 scored providers (1%). Below this entry. 30–40: 2,746 scored providers (1%). Below this entry. 40–50: 2,928 scored providers (1%). Below this entry. 50–60: 5,882 scored providers (1%). Below this entry. 60–70: 13,906 scored providers (3%). Below this entry. 70–80: 118,074 scored providers (25%). Below this entry. 80–90: 129,887 scored providers (27%). Below this entry. 90–100: 189,403 scored providers (40%). This entry sits in this band. This provider 0 100 every MIPS-scored clinician, bucketed by value

Each bar is a band; taller bars hold more scored providers. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count, share, and where it sits relative to this entry.

Source CMS Merit-based Incentive Payment System (MIPS) · 2023

Board certification likely (heuristic — not verified)

JOHN CONTI, MD practices in an ABMS-board-eligible specialty and shows active CMS Medicare participation + MIPS quality reporting + 1 hospital affiliation — signals consistent with board-certified status. For verified board certification, see CertificationMatters.org (the official ABMS public lookup).

JOHN CONTI, MD at a glance

High performer (top quartile)

NPI registry status

Active

Issued 12/20/2005

NPI 1811973084

Primary specialty

Hematology & Oncology Physician

Mid-sized

11,215 US NPIs in this specialty

Medicare Part D claims

581 31% vs specialty avg

2023 prescription claims

Specialty avg: 847

MIPS final score

93.0247/100 9.924700000000001% pts

Exceptional band

vs 83.1 national avg

Specialty distribution in New Jersey

How Hematology & Oncology Physician compares to other specialties among New Jersey providers

New Jersey providers

Hematology & Oncology Physician share within New Jersey

1. Hematology & Oncology Physician42%2. Internal medicine21%3. Family medicine17%4. Surgical12%5. Pediatric8%
Hematology & Oncology Physician share within New Jersey

Medicare quality performance — MIPS

JOHN CONTI, MD's 2023 MIPS final score plotted against the Hematology & Oncology Physician national average

High performer (top quartile)
MIPS Final Score
93.0247/100
vs 83.1 national avg · 2023 performance year

MIPS final score (Hematology & Oncology Physician) — 93.0247/100 vs national avg 83.1

0%100%National avg83%93%
MIPS final score (Hematology & Oncology Physician) — 93.0247/100 vs national avg 83.1

The Merit-based Incentive Payment System (MIPS) scores providers 0–100 across four performance categories: Quality, Cost, Promoting Interoperability, and Improvement Activities, weighted under 42 CFR §414.1380. Reporting is voluntary for many small practices, so absence of a MIPS score is not a quality signal.

Board certification through an ABMS or AOA member board signals voluntary post-licensure examination plus continuous Maintenance of Certification cycles. Verify any individual provider's status through certificationmatters.org (ABMS) or osteopathic.org (AOA).

JOHN CONTI, MD is a Hematology & Oncology Physician provider practicing in BELLEVILLE, New Jersey, according to the CMS National Plan and Provider Enumeration System (NPPES). Credentials: MD. NPI: 1811973084. This profile includes practice location, specialty classification, and organizational affiliations from the CMS provider registry. Provider information is self-reported to CMS and updated monthly.

JOHN CONTI, MD appears in the CMS NPPES registry as a Hematology & Oncology Physician provider holding MD credentials at 1 CLARA MAASS DR STE 200, BELLEVILLE, NJ, 07109, with a listed phone of (973) 751-8880. NPI 1811973084 was issued on 12/20/2005. Because NPPES data is self-reported by the provider and refreshed monthly, the address, phone, and specialty reflect what CONTI most recently submitted to CMS rather than a vetted directory listing, which is why patients should always confirm the practice is still at this location before scheduling.

Medicare Part D records for calendar year 2023 show 581 prescription claims written by this provider, covering 122 Medicare beneficiaries and totaling roughly $1.5 million in drug spend, split 24% brand-name and 76% generic by claim count. These figures capture only Medicare Part D — commercial insurance, Medicaid, and cash-pay prescriptions are not included, and any drug-beneficiary cell under 11 is suppressed by CMS for patient privacy. On the CMS Merit-based Incentive Payment System, this provider earned a Final Score of 93.0247/100 for the 2023 performance year (Quality 93.0073, Cost 65.078), compared with the national average of 83.1.

Hematology & Oncology Physician is a mid-sized specialty nationwide, with 11,215 enrolled providers across 54 states and an average of 847 Part D claims per prescriber, so the context for interpreting these metrics differs meaningfully from a primary-care baseline. Important: PlainDoctor is a directory of publicly available government data, not medical advice, a malpractice database, or a quality rating. Inclusion here does not imply a recommendation, and absence of complaints or sanctions on this page does not mean none exist — always verify credentials through the NPPES NPI Registry, your state medical board, and the ABMS or AOA before making healthcare decisions.

Practice Address

1 CLARA MAASS DR STE 200
BELLEVILLE, NJ 07109

Provider Details

NPI 1811973084
Specialty Hematology & Oncology Physician
Credentials MD
Gender Male
NPI Issued 12/20/2005

CMS Quality Score (MIPS)

Merit-based Incentive Payment System (MIPS) scores from CMS, 2023 performance year.

93.0247
Final Score
Avg: 83.1
93.0073
Quality
65.078
Cost
99
Promoting Interoperability

Reporting: Group practice

Hospital and facility affiliations

Facilities where JOHN CONTI, MD bills Medicare from. Star ratings (1-5) are CMS Hospital Compare's "Hospital overall rating" — a composite of mortality, readmission, patient experience, safety, timely care, and efficient use of medical imaging measures. Source: CMS Care Compare.

REGIONAL CANCER CARE ASSOCIATES LLC
MONTCLAIR, NJ

Affiliations sourced from CMS Doctors and Clinicians National Downloadable File; hospital ratings from CMS Hospital General Information dataset (cross-referenced by facility name + state).

Industry payments received (2024) — CMS Open Payments transparency data

The federal Physician Payments Sunshine Act (part of the Affordable Care Act) requires drug and medical-device manufacturers + group purchasing organizations to publicly report payments and other transfers of value to physicians and teaching hospitals. The data below covers 2024 for JOHN CONTI, MD. Source: openpaymentsdata.cms.gov.

Total received

$866

Largest payer

AstraZeneca Pharmaceuticals LP

Most common payment type

Food and Beverage

Industry payments are not necessarily indicators of bias — they include research funding, consulting fees for evidence-based work, royalties for inventions, food at conferences, and similar items. The disclosure exists for transparency. Read our methodology for how we interpret this data.

Brand vs generic prescribing mix · Typical

JOHN CONTI, MD — brand share 24.0%
Specialty average (est.)

24% brand-name claims vs 76% generic, on 581 2023 Medicare Part D claims.

The federal Medicare Part D Generic Dispensing Rate national benchmark sits near 90% generic / 10% brand for primary-care prescribers, per CMS Office of the Actuary 2024 estimates. Higher brand share is common in specialty prescribing where generic equivalents are not available.

Medicare Part D Prescribing Data

CMS Medicare Part D prescriber-level data for calendar year 2023.

581
Total Claims
$1.5M
Total Drug Cost
122
Medicare Beneficiaries

Prescribing Breakdown

30-Day Fills
796
Total Day Supply
21,953
Brand vs Generic
24% brand / 76% generic
Brand Drug Cost
$1.5M
Generic Drug Cost
$37K

Patient Demographics

Average Patient Age
77.0 years
Avg HCC Risk Score
1.98
Gender Split
75% female / 25% male

Top Prescribed Drugs (Medicare Part D)

Top drugs by claim count for calendar year 2023. Based on Medicare Part D data only.

Drug Claims
Letrozole
95
Hydroxyurea
42
Anastrozole
32
Sprycel
Dasatinib
20
Xgeva
Denosumab
20
Abiraterone Acetate
18
Prednisone
16
Palonosetron Hcl
14
Prochlorperazine Maleate
14
Fulvestrant
13

* Counts below 11 are suppressed by CMS for patient privacy. Generic names shown where available from CMS Part D data.

Hematology & Oncology Physician Overview

How JOHN CONTI, MD fits within the Hematology & Oncology Physician landscape nationally.

11,215
Hematology & Oncology Physician Providers in US
54
States with Hematology & Oncology Physician
847
Avg Claims per Provider

JOHN CONTI, MD's 581 claims are below the specialty average of 847.

Nearby Hematology & Oncology Physician Providers in New Jersey

Other clinicians with the same primary specialty enrolled in New Jersey, drawn from the same CMS NPPES roster as CONTI.

Compare Hematology & Oncology Physician nationally: see state-by-state distribution →

Frequently Asked Questions

What is JOHN CONTI, MD's specialty?
JOHN CONTI, MD specializes in Hematology & Oncology Physician and practices in BELLEVILLE, New Jersey. Credentials: MD.
How much does JOHN CONTI, MD prescribe under Medicare Part D?
In 2023, JOHN CONTI, MD wrote 581 Medicare Part D claims totaling $1.5M in drug costs for 122 beneficiaries.
What is JOHN CONTI, MD's Medicare quality score?
JOHN CONTI, MD has a CMS MIPS Final Score of 93.0247/100 (Quality: 93.0073, Cost: 65.078). The national average MIPS Final Score is 83.1. Source: CMS Merit-based Incentive Payment System (MIPS) 2023.
Where is JOHN CONTI, MD located?
JOHN CONTI, MD is located at 1 CLARA MAASS DR STE 200, BELLEVILLE, NJ, 07109. Phone: (973) 751-8880.
What is JOHN CONTI, MD's NPI number?
JOHN CONTI, MD's National Provider Identifier (NPI) is 1811973084, issued on 12/20/2005.
Does JOHN CONTI, MD prescribe more brand-name or generic drugs?
JOHN CONTI, MD's prescribing is 24% brand-name and 76% generic drugs by claim count, with $1.5M in brand drug costs.
How many Hematology & Oncology Physician providers are there in the US?
There are 11,215 Hematology & Oncology Physician providers across 54 states in the US. The average Hematology & Oncology Physician provider writes 847 Medicare Part D claims per year.
What drugs does JOHN CONTI, MD prescribe most often?
Based on 2023 Medicare Part D data, JOHN CONTI, MD's most frequently prescribed drugs include Letrozole, Hydroxyurea, Anastrozole. This reflects Medicare Part D prescriptions only and does not include commercial insurance or other payer types.
Does JOHN CONTI, MD accept Medicare?
JOHN CONTI, MD appears in CMS Medicare data with 581 Part D claims and 122 Medicare beneficiaries in 2023. Contact the provider's office directly to confirm current Medicare enrollment and accepted plans.
How can I verify JOHN CONTI, MD's credentials?
JOHN CONTI, MD's NPI is 1811973084 with credentials MD. You can verify this through the NPPES NPI Registry, check state medical board records, and confirm board certification through the ABMS or AOA.

Data Sources

Provider Directory
CMS National Plan and Provider Enumeration System (NPPES), download.cms.gov/nppes, updated monthly. Contains NPI, specialty, credentials, and practice location.
Specialty Classification
NUCC Health Care Provider Taxonomy (nucc.org), the industry standard for classifying provider specialties in Medicare and Medicaid billing.
Prescribing Data
CMS Medicare Part D Prescriber Public Use File (2023). Includes claims, drug costs, beneficiaries, and opioid prescribing rates.
Quality Performance
CMS Merit-based Incentive Payment System (MIPS) — 2023 performance year.
Limitations
Provider data is self-reported to CMS. Prescribing data reflects Medicare Part D only and does not include commercial insurance, Medicaid, or cash prescriptions. Claims below 11 beneficiaries are suppressed by CMS for privacy.

See our complete data methodology for details on how we collect and process government data.

Data as of April 2026 (NPPES) / 2023 (Medicare Part D). Source: Centers for Medicare & Medicaid Services (CMS).

Disclaimer: Data from CMS NPPES and Medicare Part D. PlainDoctor does not rate or rank providers. Provider information is self-reported and may not be current. Always verify information directly with the provider. About · Methodology